The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia

What this Trial Is About

Researchers are evaluating the effects of Dexamethasone on voice outcomes and hypocalcaemia in patients undergoing total thyroidectomy for benign thyroid conditions such as multinodular goitre, toxic nodular goitre, and Graves' disease. This randomized, double-blind, placebo-controlled trial aims to improve understanding of post-operative voice dysfunction and calcium level changes, which commonly affect patients after thyroid surgery. The study also explores the mechanisms of voice dysfunction using objective assessments. Participants will receive one dose of 8mg Dexamethasone injection or a placebo of 2ml normal saline during the peri-operative period. To reduce variability, surgical and anesthesia techniques are standardized across multiple hospital departments. Voice and vocal cord function will be assessed pre- and post-operatively using video stroboscopy and standardized voice assessments conducted by speech therapists. Calcium and parathyroid hormone levels will be monitored to evaluate hypocalcaemia. Throughout the study, participants will undergo voice assessments and blood tests at several time points: 1 week, 3 months, and 6 months after surgery. Researchers will measure voice handicap scores, perceptual and acoustic evaluations, aerodynamic voice function, and stroboscopic vocal cord characteristics. They will also track calcium and medication requirements and monitor for possible side effects such as wound infection. The total participation period extends up to 6 months post-operation, with careful safety monitoring during this time.

The Use of Dexamethasone in Total Thyroidectomy to Improve Voice Outcome and Hypocalcaemia